DGKα inhibition may therefore provide a rare opportunity to attack this resistant subtype/phenotype in GBM, with the potential for synergistic benefits combining DGKα inhibitors with the numerous therapies resisted by MES transition. The gene discussed is DGKA; the disease is glioblastoma.